Sign In
Buy MDGL
$513.43
+0.550 (+0.107%)
At Close: Jun 23, 2026
7 Stocks Analysts Are Loving Right Now (And You Should Too): April 2024
07:52am, Monday, 15'th Apr 2024
Many investors have one or more preferred fundamental or technical indicator. These help to cut through the noise surrounding a stock.
2 Under-the-Radar Growth Stocks to Consider
10:15am, Wednesday, 10'th Apr 2024
Madrigal Pharmaceuticals recently earned a groundbreaking therapy approval. Axsome Therapeutics is getting closer to transforming its lineup of medicines.
Better Booming Biotech Stock: Madrigal Pharmaceuticals vs. Viking Therapeutics
07:15am, Friday, 05'th Apr 2024
Madrigal Pharmaceuticals just commercialized its first medicine. Viking Therapeutics has a mid-stage candidate with great potential.
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Wednesday, 03'rd Apr 2024
CONSHOHOCKEN, Pa., April 03, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepati
1 No-Brainer Growth Stock to Buy Now
08:45am, Wednesday, 03'rd Apr 2024
Madrigal Pharmaceuticals scored a historical regulatory approval last month. Even so, the market has been taking a cautious approach to Madrigal's shares.
The 3 Best Biotech Stocks to Buy in April 2024
09:09pm, Monday, 01'st Apr 2024
Right now, biotech is one of the hottest sectors on the market, creating big opportunities for some of the best biotech stocks to buy in April. All of this is thanks to new innovation, millions of ret
Better Buy: Viking Therapeutics vs. Madrigal Pharmaceuticals
09:00am, Friday, 29'th Mar 2024
Viking's drug candidate has shown promise in clinical studies as a potential weight loss medicine. Madrigal just launched the first (and so far only) medicine approved by the U.S. for NASH.
Is This Healthcare Stock a Screaming Buy After Scoring a Huge Drug Approval?
04:43am, Friday, 29'th Mar 2024
The Food and Drug Administration recently granted accelerated approval for Rezdiffra, a potential blockbuster for Madrigal Pharmaceuticals. At its peak, the drug could bring in more than $5 billion in
2 Top Biotech Buyout Candidates
02:56pm, Thursday, 28'th Mar 2024
After a strong resurgence in the back half of 2023 and continued momentum into the first quarter of 2024, biotech stocks are back in vogue. “Hawkish” Federal Reserve Policy, a brutal bear market i
This Under-the-Radar Stock Just Hit a Major Milestone: Time to Buy?
06:15am, Friday, 22'nd Mar 2024
Madrigal earned the first approval for a medicine in an area with a high unmet need. The commercial opportunity for this therapy, which treats a liver disease, looks exciting.
Is Madrigal Pharmaceuticals Stock a Better Buy Than Eli Lilly and Novo Nordisk After Its Huge FDA Win?
05:50am, Tuesday, 19'th Mar 2024
Last week's FDA approval of Rezdiffra in treating NASH is a huge milestone for Madrigal. Lilly and Novo Nordisk look much more impressive than Madrigal in most ways.
Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering
11:58pm, Monday, 18'th Mar 2024
CONSHOHOCKEN, Pa., March 18, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatit
7 Biotech Stocks Ready to Ride the Sector's Resurgence
08:01pm, Monday, 18'th Mar 2024
Why do you want to consider biotech stocks? Simply, the narrative comes down to numbers and a possible rotation.
Madrigal Pharmaceuticals Announces Proposed Public Offering
04:04pm, Monday, 18'th Mar 2024
CONSHOHOCKEN, Pa., March 18, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatit
Madrigal: Accelerated Rezdiffra Approval Puts It In The NASH Lead
10:15am, Monday, 18'th Mar 2024
On March 14, Madrigal Pharmaceuticals, Inc. announced that the FDA has granted accelerated approval for Rezdiffra, for the treatment of adults with noncirrhotic NASH with moderate to advanced liver fi
